Our Pricing

How to Safely Manage Switching Mounjaro to Wegovy in the UK

Switching Mounjaro to Wegovy is an increasingly common consideration for patients seeking alternative GLP-1 receptor agonist therapy in the UK. Whether driven by cost considerations, supply availability, or clinical response, transitioning from tirzepatide to semaglutide requires careful medical oversight and an understanding of dose equivalence. At Cured Pharmacy, our UK-registered clinical team guides patients through evidence-based switching protocols, ensuring continuity of weight management outcomes whilst maintaining safety throughout the transition.

Understanding the Difference Before Switching Mounjaro to Wegovy

Before switching Mounjaro to Wegovy, it's essential to understand the pharmacological distinctions between these two injectable weight loss medications. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, meaning it activates both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors [1]. In contrast, Wegovy (semaglutide) is a selective GLP-1 receptor agonist that works through a single mechanism [2]. This fundamental difference explains why tirzepatide demonstrated superior weight loss outcomes in head-to-head trials, with SURPASS-2 showing 12.4kg average loss at 40 weeks versus 9.6kg with semaglutide [1].

Despite these pharmacological differences, both medications share core mechanisms that make switching Mounjaro to Wegovy a viable clinical strategy. Both slow gastric emptying, reduce appetite through central nervous system pathways, and improve glycaemic control in patients with type 2 diabetes [2]. The practical implications for switching centre on dose titration schedules and managing potential differences in gastrointestinal tolerability during the transition period. Patients should expect their prescriber to adjust dosing based on their current Mounjaro maintenance dose and individual response patterns.

Clinical Protocol for Switching Mounjaro to Wegovy Safely

The safest approach when switching Mounjaro to Wegovy involves a structured transition protocol overseen by a UK-registered prescriber. There is no universal washout period required between stopping tirzepatide and initiating semaglutide, as both medications have similar half-lives (approximately 5 days for tirzepatide and 7 days for semaglutide) [3]. Most clinicians recommend starting Wegovy at the standard 0.25mg weekly dose regardless of the Mounjaro dose being discontinued, allowing for gradual titration according to the licensed schedule.

When switching Mounjaro to Wegovy, patients currently on higher tirzepatide doses (10mg or 15mg weekly) may experience a temporary reduction in appetite suppression during the initial Wegovy titration phase. This occurs because the starting 0.25mg semaglutide dose provides lower receptor activation than therapeutic Mounjaro doses [3]. Our clinical team at Cured Pharmacy monitors this transition carefully, adjusting the titration speed based on individual tolerability and weight maintenance goals. The full Wegovy dose escalation typically spans 16-20 weeks to reach the maintenance dose of 2.4mg weekly, subject to prescriber approval.

Dose Equivalence Considerations

While no exact dose equivalence exists between tirzepatide and semaglutide due to their different mechanisms, clinical trial data provides practical guidance for switching Mounjaro to Wegovy. Patients on Mounjaro 5mg may find comparable appetite suppression with Wegovy 1.7-2.4mg, whilst those on Mounjaro 10-15mg should understand that Wegovy 2.4mg (the maximum licensed dose) may provide slightly less weight loss efficacy [1]. However, individual response variation means some patients achieve excellent outcomes with semaglutide even after higher tirzepatide doses.

Cost Analysis When Switching Mounjaro to Wegovy in the UK

Financial considerations often motivate patients towards switching Mounjaro to Wegovy, particularly given the substantial price difference between these medications in the UK private market. At Cured Pharmacy, Wegovy starts from £124.99 per month compared to Mounjaro at £124.99, representing a potential saving of £124.99 annually [4]. This cost differential becomes even more significant for long-term weight management, where treatment duration typically extends 12-24 months or longer to maintain clinical benefits.

When evaluating the economics of switching Mounjaro to Wegovy, patients should consider both the direct medication cost and the value of weight loss outcomes. Whilst Mounjaro demonstrated superior weight reduction in clinical trials (averaging 2.8kg more loss than semaglutide at comparable time points), Wegovy still achieved clinically significant results with 14.9% average body weight reduction at 68 weeks in the STEP 1 trial [2]. For many patients, the substantial cost savings justify switching Mounjaro to Wegovy, particularly when combined with lifestyle interventions that optimise outcomes with either medication. New patients can save an additional £20 off their first order with code Weightlossnew.

Managing Side Effects When Switching Mounjaro to Wegovy

Gastrointestinal tolerability represents the primary concern when switching Mounjaro to Wegovy, as both medications share similar adverse effect profiles dominated by nausea, diarrhoea, and constipation [2]. Interestingly, some patients report improved tolerability after switching from tirzepatide to semaglutide, whilst others experience the opposite. This individual variation stems from differences in GIP receptor activation and the rate of gastric emptying between the two medications [3].

To minimise side effects when switching Mounjaro to Wegovy, our clinical team recommends starting with the standard 0.25mg Wegovy dose even if you were tolerating higher Mounjaro doses well. This conservative approach allows your gastrointestinal system to adapt to semaglutide's specific pharmacodynamic profile [3]. Practical strategies include taking the injection on the same day each week (maintaining consistency from your Mounjaro schedule), eating smaller meals more frequently, staying well-hydrated, and avoiding high-fat foods during the initial titration weeks. If nausea persists beyond the first month of switching Mounjaro to Wegovy, consult your prescriber about slowing the dose escalation schedule.

Injection Technique and Administration

The practical aspects of switching Mounjaro to Wegovy include adapting to different pen devices, though both are administered as weekly subcutaneous injections. Wegovy pens are single-dose, pre-filled devices that require minimal preparation, similar to Mounjaro KwikPens. Patients should continue rotating injection sites (abdomen, thigh, or upper arm) to reduce the risk of lipohypertrophy and maintain consistent absorption. The injection can be administered at any time of day, with or without meals, though maintaining the same day each week optimises consistency.

Expected Outcomes After Switching Mounjaro to Wegovy

Patients switching Mounjaro to Wegovy typically maintain their weight loss rather than continuing the rapid reduction phase experienced during initial tirzepatide treatment. In clinical practice, most individuals who switch after achieving significant weight loss on Mounjaro (e.g., 10-15% body weight reduction) find that Wegovy effectively prevents weight regain whilst some continue gradual loss as they titrate to the 2.4mg maintenance dose [2]. The key to success lies in maintaining the dietary and lifestyle modifications established during Mounjaro treatment.

Long-term data on switching Mounjaro to Wegovy remains limited, as tirzepatide only received UK marketing authorisation for weight management in 2023. However, extensive real-world evidence supports sustained weight loss with semaglutide 2.4mg over 2+ years when combined with behavioural interventions [2]. Patients should set realistic expectations: switching primarily offers cost savings and continued weight maintenance rather than enhanced efficacy. Those who experienced suboptimal results on Mounjaro are unlikely to see dramatically improved outcomes after switching Mounjaro to Wegovy, and may benefit from discussing alternative strategies with their prescriber.

How to Access Wegovy After Switching Mounjaro to Wegovy at Cured Pharmacy

Switching Mounjaro to Wegovy through Cured Pharmacy begins with a free online clinical assessment that takes under 3 minutes to complete. Our UK-registered prescribers review your current tirzepatide dose, weight loss progress, medical history, and switching rationale to ensure semaglutide represents an appropriate alternative. This assessment is mandatory for all prescription weight loss medications under MHRA regulations, even for patients already established on GLP-1 therapy [4].

Once approved for switching Mounjaro to Wegovy, your medication is dispensed by our GPhC-registered pharmacy (registration 9012511) and delivered in 100% discreet packaging with next-day delivery options available. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services, ensuring every patient receives the same standard of care expected from traditional community pharmacy settings. Our transparent pricing model means you see the exact cost before completing your consultation—Wegovy from £124.99 with no hidden fees. For ongoing support during your transition, our clinical team remains available via phone (+44 116 4646009) or secure messaging to address any concerns about tolerability, dosing, or weight management strategies.

Prescription Requirements and Eligibility

Eligibility criteria for switching Mounjaro to Wegovy mirror the requirements for initiating any GLP-1 weight loss therapy: BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea). Patients already established on Mounjaro typically meet these criteria, though prescribers will verify that continued GLP-1 therapy remains clinically appropriate based on weight loss response and tolerability. All treatment decisions are made by independent UK prescribers following NICE and MHRA guidance.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.